Algos Selects Methadex As Tradename For Heroin Abuse Therapy
This article was originally published in Pharmaceutical Approvals Monthly
Algos Pharmaceutical has chosen the tradename Methadex for a combination methadone/dextromethorphan product in Phase II trials for treatment of heroine addiction. The company filed the name with the Patent and Trademark Office for analgesic and anesthetic preparations.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class